

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jinxin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

**VOLUNTARY ANNOUNCEMENT
PROPOSED LAUNCH OF ASSET-BACKED SECURITIES PROGRAMME
ON THE SHANGHAI STOCK EXCHANGE**

This announcement is made by Jinxin Fertility Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company is considering to launch an asset-backed securities program (“**ABS Program**”) involving the issue of a single class of securities (“**ABS**”) based on the underlying assets of a subsidiary of the Company, namely, Shenzhen Hengyu Lianxiang Investment Development Co., Ltd.* (深圳市恒裕聯翔投資發展有限公司) (“**Hengyu**”). Such underlying assets comprise predominantly real property in the form of a building currently owned by Hengyu located at Futian District, Shenzhen, China which is currently used by the Group’s Shenzhen Zhongshan Hospital, and it is intended that the ABS will be traded on the Shanghai Stock Exchange (the “**Proposed Transaction**”). If the Proposed Transaction is successfully completed, it is expected to significantly reduce the Company’s prevailing leverage ratio and optimize capital structure and asset quality.

In the event that the Company proceeds with the Proposed Transaction, it may constitute a deemed disposal of Hengyu under Rule 14.29 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The Company will apply for the approvals from relevant regulatory authorities including, but not limited to, China Securities Regulatory Commission, the Shanghai Stock Exchange and the Stock Exchange of Hong Kong Limited, in relation to the Proposed Transaction in due course.

As at the date of this announcement, the details and terms of the Proposed Transaction have yet to be finalized. The Company will make further announcement(s) in connection with the Proposed Transaction as and when appropriate or required in accordance with the requirements of the Listing Rules.

Shareholders and potential investors should note that the Proposed Transaction is subject to, among other things, the prevailing market conditions and approvals from relevant regulatory authorities. Accordingly, the Proposed Transaction may or may not take place. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang
*Chief Executive Officer,
Acting Chief Financial Officer
and Executive Director*

Hong Kong, June 22, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Dong Yang, Dr. Lyu Rong and Dr. Geng Lihong, as executive Directors; Mr. Zhong Yong, as Chairman and non-executive Director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive Directors; and Dr. Chong Yat Keung, Dr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.

* *For identification purposes only*